Market Place
Sourcing Support
Disc Host Call on Ph 2 FDA Meeting for Bitopertin in Protoporphyria
01 Nov 2024 //
GLOBENEWSWIRE
Disc Medicine Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Disc Reports Topline Results from Ph 2 Study of Bitopertin in Patients with EPP
01 Apr 2024 //
GLOBENEWSWIRE
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin
11 Dec 2023 //
GLOBENEWSWIRE
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Trial of Bitopertin
27 Jul 2023 //
GLOBENEWSWIRE
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin
27 Dec 2022 //
PRNEWSWIRE
Disc Medicine Initiates AURORA, a Phase 2 Study of Bitopertin with EPP
31 Oct 2022 //
PRNEWSWIRE
Gemini’s fall gives Disc a way around biotech’s IPO slump
11 Aug 2022 //
BIOPHARMADIVE
Disc Medicine Announces Oral Presentation on Bitopertin at 63rd ASH
11 Nov 2021 //
FIRSTWORDPHARMA
Roche schizophrenia drug that failed PhIII gets a new life
02 Sep 2021 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.